{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=methylprednisolone+acetate&page=7", "query": { "intervention": "methylprednisolone acetate", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 582, "total_pages": 59, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=methylprednisolone+acetate&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=methylprednisolone+acetate&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T21:02:32.949Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01524068", "title": "A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "Standard Steroid Treatment", "type": "DRUG" }, { "name": "The Standard Steroid Treatment, Plasma Exchange and rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 0, "start_date": "2012-09", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2016-01-05", "last_synced_at": "2026-10-09T21:02:32.949Z", "location_count": 5, "location_summary": "Danville, Pennsylvania • Philladelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Danville", "state": "Pennsylvania" }, { "city": "Philladelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Galveston", "state": "Texas" }, { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01524068" }, { "nct_id": "NCT00002718", "title": "T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "in vitro-treated bone marrow transplantation", "type": "PROCEDURE" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "49 Years", "sex": "ALL", "summary": "Up to 49 Years" }, "enrollment_count": 31, "start_date": "1995-11", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2015-12-23", "last_synced_at": "2026-10-09T21:02:32.949Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002718" }, { "nct_id": "NCT05643638", "title": "A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease, Acute" ], "interventions": [ { "name": "CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Corticosteroids", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Cynata Therapeutics Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-03-04", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-09T21:02:32.949Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05643638" }, { "nct_id": "NCT01391793", "title": "Corticosteroids for Children With Febrile Urinary Tract Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Urinary Tract Infection", "Urinary Tract Infection" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nader Shaikh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "6 Years", "sex": "ALL", "summary": "2 Months to 6 Years" }, "enrollment_count": 546, "start_date": "2011-09", "completion_date": "2018-03-30", "has_results": true, "last_update_posted_date": "2019-07-02", "last_synced_at": "2026-10-09T21:02:32.949Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01391793" }, { "nct_id": "NCT06209606", "title": "Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ruxolitinib Oral Tablet [Jakafi]", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-12-08", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2024-12-17", "last_synced_at": "2026-10-09T21:02:32.949Z", "location_count": 1, "location_summary": "West Hollywood, California", "locations": [ { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06209606" }, { "nct_id": "NCT00186628", "title": "Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Mast-Cell", "Mantle-cell Lymphoma" ], "interventions": [ { "name": "Total lymphoid irradiation", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Anti-thymoglobulin, rabbit (ATG, rabbit ATG)", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenylate mofetil", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Granisetron", "type": "DRUG" }, { "name": "Solumedrol", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "76 Years", "sex": "ALL", "summary": "18 Years to 76 Years" }, "enrollment_count": 36, "start_date": "2005-06", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2017-11-28", "last_synced_at": "2026-10-09T21:02:32.949Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00186628" }, { "nct_id": "NCT06729593", "title": "Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Remdesivir", "type": "BIOLOGICAL" }, { "name": "Remdesivir Placebo", "type": "BIOLOGICAL" }, { "name": "Corticosteroid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2021-04-20", "completion_date": "2022-11-20", "has_results": true, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-10-09T21:02:32.949Z", "location_count": 40, "location_summary": "Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06729593" }, { "nct_id": "NCT06489626", "title": "The Effect of a Methylprednisolone Taper on Outcomes Following Total Knee Arthroplasty", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Arthritis Knee", "Knee Osteoarthritis", "Pain, Postoperative" ], "interventions": [ { "name": "Methylprednisolone 4 milligram Tab", "type": "DRUG" }, { "name": "Dexamethasone injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "F. Johannes Plate", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-11-01", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-09T21:02:32.949Z", "location_count": 2, "location_summary": "Monroeville, Pennsylvania • Pittsburgh, Pennsylvania", "locations": [ { "city": "Monroeville", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06489626" }, { "nct_id": "NCT05626478", "title": "Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Corneal Edema", "Corneal Defect", "Anterior Chamber Inflammation", "Ocular Pain", "Corneal Staining", "Visual Outcome", "CME - Cystoid Macular Edema" ], "interventions": [ { "name": "Dextenza 0.4Mg Ophthalmic Insert", "type": "DRUG" }, { "name": "Prednisolone Acetate 1% Oph Susp", "type": "DRUG" }, { "name": "Prolensa 0.07% Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nicole Fram M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-06-01", "completion_date": "2025-02-05", "has_results": false, "last_update_posted_date": "2026-02-20", "last_synced_at": "2026-10-09T21:02:32.949Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05626478" }, { "nct_id": "NCT00689078", "title": "Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Allergic Conjunctivitis" ], "interventions": [ { "name": "Prednisolone Acetate 1%", "type": "DRUG" }, { "name": "Prednisolone Acetate 0.12%", "type": "DRUG" }, { "name": "Loteprednol Etabonate 0.2%", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ORA, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2008-05", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2020-09-02", "last_synced_at": "2026-10-09T21:02:32.949Z", "location_count": 1, "location_summary": "Andover, Massachusetts", "locations": [ { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00689078" } ] }